Novo Nordisk CEO sounds alarm on EU reform for cheaper medicines

Everyone will be conducting clinical trials in the US in the future, says the Novo CEO.
Photo: Stine Bidstrup
Photo: Stine Bidstrup
by marketwire

Shorter patent protection make it difficult for pharmaceutical companies to recoup the money they have spent on drug development and could ultimately send European drug development to the US, warns Lars Fruergaard Jørgensen, CEO of Novo Nordisk, in an interview with news agency Reuters.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Photo: Mike Blake/Reuters/Ritzau Scanpix

    Gilead Sciences CMO to leave early 2025

    For subscribers

    Further reading